Share

    


Home / Search Results

Search Results

You searched for:

Key takeaways from day 1 of #ACCCNOC.
If you are looking for legislative action, look no further than your state's legislatures. Most—if not all—states have had issues relating to oncology care and healthcare in general come up during their 2023 sessions.
On June 1, 2021, the Governor of Louisiana signed legislation that banned “white bagging” in the state, ensuring that health insurers cannot refuse to pay for approved physician-administered drugs and related services to covered patients. It is the first such law in the United States.
Over the last several months, ACCC members have experienced a rising trend of payer-mandated white and brown bagging. ACCC will continue to monitor and update members about issues related to white and brown bagging.
Insurer mandates requiring patients to have their therapies dispensed via “brown bagging” or “white bagging” are becoming increasingly common. Oncologists treating patients whose insurers require these methods of pharmaceutical procurement have identified problematic issues with them, including concerns about patient safety, proper care coordination, potential treatment delays, and drug waste.
"One of the greatest challenges we face over the next decade is related to our oncology workforce. Specifically, will we have enough providers and staff to support and deliver lifesaving treatments to patients?" Olalekan Ajayi, PharmD, MBA Chief Operating Officer for Highlands Oncology Group, PA President of the Association of Community Cancer Centers (ACCC)
In the parlance of drug dispensing, “white bagging” is the term used when insurers require certain prescribed drugs to be dispensed from a specific specialty pharmacy and shipped directly to a practice, hospital, or clinic for patient administration. This is increasingly the case with infusion therapies for the treatment of cancer. Many providers are taking a stand against insurer mandates for …
On February 2, 2022, President Biden announced plans to revamp the federal Cancer Moonshot program he spearheaded in 2016, with a goal of reducing the cancer death rate by at least 50% over the next 25 years and improving the experience of people and their families living with and surviving cancer by increasing cancer screenings, increasing access to clinical trials, and investing in new …